Clinical trials: Gram-positive Bacterial Infections
Tuberculosis, Tuberculosis (TB)
Questioning the Epidemiology of Asymptomatic TB
Tuberculosis (TB) remains one of the world's leading causes of morbidity and mortality. Current TB control strategies focus largely on the binary paradigm of TB, which tackle Mtb infection and the symptomatic stages of the…
- Conditions
- Tuberculosis, Tuberculosis (TB), HIV, HIV (Human Immunodeficiency Virus)
- Trial name
- TB QUEST (NCT07312266)
- Where
- Mozambique
- Volunteers
- 6,770 people, healthy volunteers welcome
- Sponsor
- Barcelona Institute for Global Health
Infections, Streptococcal
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A, Zilbrix™ Hib and Polio Sabin™
The purpose of this study is to assess the immunogenicity in terms of antibody response and the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of…
- Trial name
- NCT00678301
- Testing
- GSK Biologicals' Synflorix™, GSK Biologicals' Polio Sabin™, GSK Biologicals' Zilbrix™ Hib
- Where
- 2 sites in Mali, Nigeria
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pulmonary Tuberculosis
Prospective Assessment of TBDx Feasibility
The purpose of this study will be to determine the performance characteristics of TBDx with culture as a gold standard. In addition, the investigators will assess the laboratory technicians' appraisal and technical suitability of…
- Trial name
- NCT02912832
- Testing
- TBDx
- Where
- 2 sites in Peru, Vietnam
- Volunteers
- 572 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tetanus, Haemophilus Influenzae Type b
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age
This study will evaluate the safety and reactogenicity of GSK Biologicals' Diphtheria Tetanus acellular Pertussis/Haemophilus influenzae type b vaccine given to Chinese infants at 3, 4 and 5 months of age.
- Conditions
- Tetanus, Haemophilus Influenzae Type b, Acellular Pertussis, Diphtheria
- Trial name
- NCT00379977
- Testing
- diphtheria, tetanus, pertussis & Hib vaccine
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Clostridium Infections
C.Difficile Observational Study
D8820C00001 is an exploratory, non-interventional, unblinded, observational study evaluating the acceptability, feasibility and performance of methods to collect, transport and test biospecimens in participants ≥ 18 years of age…
- Trial name
- NCT06277999
- Where
- 7 sites in United States
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Tuberculosis
A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
The purpose of this study is to determine whether a subunit tuberculosis vaccine given as two nasal immunizations composed of a hybrid protein antigen from M.
- Trial name
- TMUVA-01 (NCT00440544)
- Testing
- Ag85B-ESAT6 fusion protein H1
- Where
- United Kingdom
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- St George's, University of London
Pneumonia, Bacterial, Cancer
Impact of Pharmacist-led Educational Intervention on Pneumococcal Vaccination Rates in Cancer Patients
According to the World Health Organization (WHO), immunization; is defined as making a person immune or resistant to an infectious disease by applying a vaccine (1).
- Conditions
- Pneumonia, Bacterial, Cancer, Pneumococcal Infections
- Trial name
- NCT05229081
- Testing
- vaccine education
- Where
- Turkey (Türkiye)
- Volunteers
- 228 people
- Sponsor
- Hacettepe University
Infection, Bacterial, Anthrax
An Open Label Field Study of Anthim (Obiltoxaximab) in Subjects Exposed to B. Anthracis
This field study is a post-marketing requirement from the FDA to evaluate the clinical benefit (course of illness and survival), safety and pharmacokinetics of obiltoxaximab administered to patients as part of their medical care…
- Trial name
- NCT03088111
- Testing
- Collection of samples, Obiltoxaximab
- Volunteers
- 100 people
- Sponsor
- Elusys Therapeutics
Infections, Meningococcal
Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects
The purpose of this study is to assess the safety and reactogenicity of a booster dose of diphtheria-tetanus-whole cell pertussis-hepatitis B virus/Haemophilus influenzae type b vaccine (DTPw-HBV/Hib) at 15-18 m and to assess the…
- Trial name
- NCT00317109
- Testing
- Tritanrix™- HepB, Hiberix™, Mencevax™ ACW
- Where
- 3 sites in South Africa
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Poliomyelitis, Diphtheria
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infants
The purpose of this study is to assess the immunogenicity and safety of GSK Biologicals' Infanrix hexa vaccine when administered to healthy infants as primary vaccination at 2, 4 and 6 months of age, co-administered with Prevnar…
- Conditions
- Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus
- Trial name
- NCT02096263
- Testing
- Infanrix hexa, Pediarix, ActHIB
- Where
- 43 sites in United States
- Volunteers
- 585 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, HIV
Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya
In 2012, the WHO Strategic Advisory Group of Experts (SAGE) concluded that pregnant women are the most important risk group for season influenza vaccination based upon "compelling evidence of substantial risk of severe disease in…
- Conditions
- Influenza, Human, HIV, Malaria, Tetanus
- Trial name
- NCT01810731
- Testing
- Quadrivalent Inactivated Influenza Vaccine (QIV), Inactivated Polio Vaccine, Double Dose QIV
- Where
- Kenya
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB…
- Conditions
- Tuberculosis, Multidrug-Resistant, Extensively Drug-Resistant Tuberculosis, Tuberculosis, Pulmonary
- Trial name
- TB-PRACTECAL (NCT02589782)
- Testing
- Bedaquiline, Pretomanid, Moxifloxacin
- Where
- 7 sites in Belarus, South Africa and 1 more
- Volunteers
- 552 people
- Sponsor
- Medecins Sans Frontieres, Netherlands
Tuberculosis
PPD Size and Mycobacteria Tuberculosis ELISPOT in Children Who Have Received BCG in Neonate Period
To investigate the size of PPD and TB specific ELISPOT among children between 3m/o and 15 y/o . Calculate the normal range of age specific PPD size in children who recieved BCG at new-born period.
- Trial name
- NCT00172783
- Where
- Taiwan
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Tuberculosis
Potential Role of Microbiome in Tuberculosis
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly infectious disease and major global public health problem.
- Trial name
- Micro-STOP (NCT04985994)
- Where
- 2 sites in Pakistan
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- Khyber Medical University Peshawar
Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence
STOP-CDI: Efficacy of Fecal Microbiota Transplantation vs Fidaxomicin vs Vancomycin in Treating and Preventing Relapse of Clostridioides Difficile Infection
The STOP-CDI study is a multicenter, randomized, open-label, three-arm clinical trial comparing the efficacy of fecal microbiota transplantation (FMT) preceded by vancomycin, fidaxomicin monotherapy, and standard-of-care…
- Conditions
- Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Fecal Microbiota Transplantation (FMT), Comparative Effectiveness of CDI Treatments
- Trial name
- STOP-CDI (NCT07120490)
- Testing
- FMT (fecal microbiota transplantation), Fidaxomicin, Vancomycin (VAN) treatment
- Volunteers
- 424 people
- Sponsor
- Medical University of Warsaw
Tuberculosis
Rapid Diagnosis of Pulmonary Tuberculosis
The purpose of this study is to test whether a saline nebulization (breathing in a mist of moist air through a mask) will help an individual cough up a better sputum sample to test for tuberculosis (TB).
- Trial name
- NCT00608790
- Testing
- Salbutamol, Sodium chloride 5%
- Where
- South Africa
- Volunteers
- 600 people
- Sponsor
- University of Cape Town
Rheumatic Heart Disease, Heart Failure
Dapagliflozin Effect on Rheumatic Mitral Stenosis
Rheumatic mitral stenosis remains a health problem in developing countries. Progressive fibrosis of the valves and myocardium is the main pathophysiology that plays an important role.
- Conditions
- Rheumatic Heart Disease, Heart Failure, Mitral Stenosis
- Trial name
- Dapa-Rhemis (NCT05618223)
- Testing
- Dapagliflozin
- Where
- Indonesia
- Volunteers
- 36 people
- Sponsor
- Universitas Sebelas Maret
Atopic Dermatitis, Eczema Herpeticum
Registry for the Atopic Dermatitis Research Network
The purpose of this multi-center, clinical registry study is to determine genetic markers associated with susceptibility of AD patients to infections and to also serve as a potential participant database for future studies.
- Trial name
- NCT01494142
- Where
- 9 sites in United States
- Volunteers
- 3,387 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Clostridioides Difficile Infection
Long-Term Outcomes After CDI: FMT Versus Antibiotic-Only Treatment
The goal of this observational study is to learn about the long-term effects of fecal microbiota transplantation (FMT) compared with antibiotic-only treatment in adults who were treated for Clostridioides difficile infection…
- Trial name
- LTO-CDI (NCT07569380)
- Where
- Sweden
- Volunteers
- 250 people
- Sponsor
- Umeå University
Tuberculosis, Tuberculosis Infection
Immunological Biomarkers in Tuberculosis Management
Tuberculosis (TB) is the leading cause of death by infectious disease in the world, responsible for 1.6 million deaths in 2017. The treatment of active TB requires at least a 6-month combined antibiotic regimen and can cause…
- Trial name
- OPTI-4TB (NCT04271397)
- Testing
- Multiple blood samples, Single blood sample
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Hospices Civils de Lyon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.